Mitsubishi UFJ Asset Management
DSGN icon

Mitsubishi UFJ Asset Management’s Design Therapeutics DSGN Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,306
Closed -$111K – 1117
2023
Q1 		$111K Buy
19,306
+2,617
+16% +$19.6K ﹤0.01% 1083
2022
Q4 		$163K Buy
+16,689
New +$226K ﹤0.01% 1043

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mitsubishi UFJ Asset Management's DSGN Position: Q2 2023 in Review

Mitsubishi UFJ Asset Management sold out of Design Therapeutics (DSGN) in Q2 2023, closing a stake of 19,306 shares — an estimated $111K sold.

Mitsubishi UFJ Asset Management first reported a position in DSGN in Q4 2022 and held it in 2 quarters. The position peaked at $163K in Q4 2022. 97 funds tracked by Wall St. Rank hold DSGN as of Q2 2023.

  • Mitsubishi UFJ Asset Management reported no remaining Design Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 19,306 Design Therapeutics shares in Q2 2023, an estimated $111K.
  • Mitsubishi UFJ Asset Management first reported a position in Design Therapeutics in Q4 2022 and held it in 2 quarters.
  • Mitsubishi UFJ Asset Management's Design Therapeutics position peaked at $163K in Q4 2022.
  • 97 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2023.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.